Alexander Y. Walley MD
Professor, General Internal Medicine
Courtesy Staff Privileges, Medicine
801 Massachusetts Ave | (617) 414-6975
General Internal Medicine
Clinical Addiction Research and Education Unit
Evans Center for Interdisciplinary Biomedical Research
Dr Walley is Professor of Medicine and an addiction expert at Boston Medical Center and Boston University School of Medicine. Dr Walley has conducted multiple studies related to the opioid crisis and the integration of addiction specialty care and general medical care. He has served as PI on a CDC-SAMHSA-Epi-AID investigation of the surge in fentanyl-related overdose, a CDC-funded study of the Massachusetts OEND program which demonstrated community-level reductions in overdose death rates, and a SAMHSA-funded program that integrated addiction treatment into the clinical care of people with/at risk for HIV. He has worked as Co-I with addiction, overdose, and HIV expertise on NIDA and NIAAA-funded clinical trials and cohort studies.
Dr Walley is the director of the Boston Medical Center Addiction Medicine Fellowship program, as well as the director the NIDA-funded Fellow Immersion Training program in Addiction Medicine, which trains 5 subspecialty fellows each year to integrate addiction science into their subspecialty research. He provides primary care and addiction medicine consultations in the HIV primary care clinic at Boston University School of Medicine/BMC where he leads the FAST PATH (Facilitated Access to Substance abuse Treatment for Prevention and Treatment of HIV) program. Dr Walley co-founded and provides care on the inpatient addiction consult service at Boston Medical Center, which regularly provides consultation for patients admitted to the hospital who use alcohol and substances. Lastly, Dr Walley has been the medical director of the Massachusetts Opioid Overdose Prevention program since it started in 2007. They have trained and equipped over 100,000 people in the community with naloxone rescue kits, culminating in over 25,000 documented overdose rescues.
Medicine-Internal, MD, Johns Hopkins University School of Medicine, 2002
Epidemiology, MSc, Boston University School of Public Health, 2007
History and Literature, AB, Harvard College, 1993
Braun HM, Jones EK, Walley AY, Siegel J, Streed CG. Characterizing Substance Use Disorders among Transgender Adults Receiving Care at a Large Urban Safety Net Hospital. J Addict Med. 2021 Sep 22. PMID: 34561349.Published on 9/2/2021
Zang X, Macmadu A, Krieger MS, Behrends CN, Green TC, Morgan JR, Murphy SM, Nolen S, Walley AY, Schackman BR, Marshall BD. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. Int J Drug Policy. 2021 Sep 02; 98:103435. PMID: 34482264.Published on 8/29/2021
Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, Turnbull J. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int J Drug Policy. 2021 Aug 29; 98:103400. PMID: 34469781.Published on 8/23/2021
Pollini RA, Slocum S, Ozga J, Joyce R, Xuan Z, Green TC, Walley AY. Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study. J Am Pharm Assoc (2003). 2021 Aug 23. PMID: 34511372.Published on 6/1/2021
Kimmel S, Bach P, Walley AY. Treatment of Refractory Opioid Use Disorder : Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: A Narrative Review. J Gen Intern Med. 2021 06; 36(6):1793. PMID: 33772440.Published on 5/21/2021
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764. PMID: 34051547.Published on 4/30/2021
Park TW, Sikov J, dellaBitta V, Saitz R, Walley AY, Drainoni ML. "It could potentially be dangerous... but nothing else has seemed to help me.": Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. J Subst Abuse Treat. 2021 Apr 30; 131:108455. PMID: 34098286.Published on 4/20/2021
Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021 07 01; 224:108703. PMID: 33964730.Published on 4/9/2021
Jawa R, Rozansky H, Clemens D, Fagan M, Walley AY. Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs: An Opportunity for Change in the Time of COVID-19. J Addict Med. 2021 Apr 09. PMID: 33870955.Published on 4/1/2021
Kerensky T, LaRochelle M, Fan SL, Kosakowski S, Wason K, Walley AY. Non-prescription Fentanyl Positive Toxicology: Prevalence, Positive Predictive Value of Fentanyl Immunoassay Screening, and Description of Co-substance Use. J Addict Med. 2021 04 01; 15(2):150-154. PMID: 32909981.
Published on 7/9/2021
Published on 9/11/2020
Published on 6/22/2020
Published on 4/16/2020
Published on 4/15/2020
Published on 3/5/2020
Published on 2/26/2020
Published on 2/25/2020
Published on 2/25/2020
Published on 2/25/2020View full list of 26 media mentions.